{"product_id":"mild-cognitive-impairment-and-early-alzheimers-disease-detection-and-diagnosis-hardback-9780470319369","title":"Mild Cognitive Impairment and Early Alzheimer's Disease; Detection and Diagnosis (Hardback) 9780470319369","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eMild Cognitive Impairment and Early Alzheimer's Disease\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eDetection and Diagnosis\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eJeffrey M. Burns (Author), John C. Morris (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470319369, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 18 April 2008\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e160 pages\u003cbr\u003e21.2 x 15.7 x 1.4 cm, 0.397 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eWritten by leading authorities in the field, this book describes the cognitive changes associated with age, the earliest detectable stages of Alzheimer’s, and the relationship of these conditions to MCI. The authors review the latest advances in our understanding of MCI, its prevalence, evaluation, management, and outcomes and in so doing provide practising physicians with a useful resource that assists them in identifying those MCI patients who will progress to recognised Alzheimer’s Disease.  \u003cp\u003eBeautifully presented in full colour, \u003cb\u003e\u003ci\u003eEarly Diagnosis and Treatment of Mild Cognitive Impairment\u003c\/i\u003e\u003c\/b\u003e includes case studies and discusses future therapeutic and diagnostic strategies. It is an invaluable resource for postgraduates and professionals, for specialist physicians in neurology and psychiatric medicine, geriatric medicine and general practice.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cb\u003e1. Introduction.\u003c\/b\u003e  \u003cp\u003eWhat is mild cognitive impairment?\u003c\/p\u003e \u003cp\u003eEpidemiological studies of MCI.\u003c\/p\u003e \u003cp\u003eThe border zone between aging and dementia: cognitive and neuropathological changes.\u003c\/p\u003e \u003cp\u003eAging and cognitive performance.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Neuropathology of Alzheimer’s disease, non-demented aging and MCI.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHistopathological features.\u003c\/p\u003e \u003cp\u003ePlaques.\u003c\/p\u003e \u003cp\u003eNeurofibrillary pathology.\u003c\/p\u003e \u003cp\u003eNeuronal loss.\u003c\/p\u003e \u003cp\u003eTopography of neuropathological changes.\u003c\/p\u003e \u003cp\u003eNeuropathological AD diagnosis.\u003c\/p\u003e \u003cp\u003eNeuropathology of aging.\u003c\/p\u003e \u003cp\u003eNeuropathology of MCI.\u003c\/p\u003e \u003cp\u003eDoes a subset of MCI patients actually have early Alzheimer’s disease?\u003c\/p\u003e \u003cp\u003eClinical studies.\u003c\/p\u003e \u003cp\u003eNeuroimaging.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Detecting and diagnosing MCI and early AD.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEarly detection.\u003c\/p\u003e \u003cp\u003eRecognition of MCI and early AD.\u003c\/p\u003e \u003cp\u003eInformant-based history.\u003c\/p\u003e \u003cp\u003eNeurological examination.\u003c\/p\u003e \u003cp\u003eLaboratory and radiological evaluation.\u003c\/p\u003e \u003cp\u003ePsychometric\/mental status testing.\u003c\/p\u003e \u003cp\u003eDementia-screening instruments.\u003c\/p\u003e \u003cp\u003eMini-mental state examination.\u003c\/p\u003e \u003cp\u003eClock-drawing test.\u003c\/p\u003e \u003cp\u003eSeven-minute screen.\u003c\/p\u003e \u003cp\u003eDementia staging instruments.\u003c\/p\u003e \u003cp\u003eCDR.\u003c\/p\u003e \u003cp\u003eGlobal deterioration scale.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Etiology of MCI: differential diagnosis.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e“Worried-well”.\u003c\/p\u003e \u003cp\u003eDepression.\u003c\/p\u003e \u003cp\u003eOther etiologies.\u003c\/p\u003e \u003cp\u003eNeurodegenerative dementias.\u003c\/p\u003e \u003cp\u003eOverlap disorders.\u003c\/p\u003e \u003cp\u003eDementia with Lewy bodies.\u003c\/p\u003e \u003cp\u003eVascular dementia.\u003c\/p\u003e \u003cp\u003eFrontotemporal lobar dementias.\u003c\/p\u003e \u003cp\u003eIdentifying the subset of MCI that is AD.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. Treatment of MCI and dementia.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMCI.\u003c\/p\u003e \u003cp\u003eThe case for early treatment.\u003c\/p\u003e \u003cp\u003eNon-pharmacological treatment.\u003c\/p\u003e \u003cp\u003eDementia therapy.\u003c\/p\u003e \u003cp\u003eApproved therapies.\u003c\/p\u003e \u003cp\u003eCholinergic hypothesis.\u003c\/p\u003e \u003cp\u003eCholinesterase inhibitors.\u003c\/p\u003e \u003cp\u003eDonepezil.\u003c\/p\u003e \u003cp\u003eRivastigmine.\u003c\/p\u003e \u003cp\u003eGalantamine.\u003c\/p\u003e \u003cp\u003eMemantine.\u003c\/p\u003e \u003cp\u003eAgents under investigation for AD treatment and prevention.\u003c\/p\u003e \u003cp\u003eVitamin E and selegiline.\u003c\/p\u003e \u003cp\u003eEstrogen.\u003c\/p\u003e \u003cp\u003eAnti-inflammatory agents.\u003c\/p\u003e \u003cp\u003eCholesterol-reducing agents.\u003c\/p\u003e \u003cp\u003eChelation therapy.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. Future therapeutic and diagnostic strategies.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAmyloid hypothesis.\u003c\/p\u003e \u003cp\u003eSecretase inhibitors.\u003c\/p\u003e \u003cp\u003eAmyloid vaccine.\u003c\/p\u003e \u003cp\u003ePotential biomarkers.\u003c\/p\u003e \u003cp\u003eCSF biomarkers.\u003c\/p\u003e \u003cp\u003eCSF amyloid beta (Aβ).\u003c\/p\u003e \u003cp\u003eCSF tau.\u003c\/p\u003e \u003cp\u003eCSF sulfatide.\u003c\/p\u003e \u003cp\u003eCSF markers of inflammation.\u003c\/p\u003e \u003cp\u003eCSF markers of oxidative stress.\u003c\/p\u003e \u003cp\u003eSerum biomarkers.\u003c\/p\u003e \u003cp\u003eStructural imaging.\u003c\/p\u003e \u003cp\u003eFunctional neuroimaging.\u003c\/p\u003e \u003cp\u003ePET and SPECT.\u003c\/p\u003e \u003cp\u003eFunctional MRI (fMRI).\u003c\/p\u003e \u003cp\u003eImaging amyloid.\u003c\/p\u003e \u003cp\u003eGenetic testing.\u003c\/p\u003e \u003cp\u003eEarly-onset familial AD.\u003c\/p\u003e \u003cp\u003eAmyloid precursor protein.\u003c\/p\u003e \u003cp\u003ePresenilin genes.\u003c\/p\u003e \u003cp\u003eLate-onset AD.\u003c\/p\u003e \u003cp\u003eApolipoprotein E.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Case studies.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCase report 1: MCI as early-stage Alzheimer’s disease.\u003c\/p\u003e \u003cp\u003eComment.\u003c\/p\u003e \u003cp\u003eCase report 2: Diagnosis of dementia prior to impairment sufficient for MCI.\u003c\/p\u003e \u003cp\u003eComment.\u003c\/p\u003e \u003cp\u003eCase report 3: Memory complaints associated with non-demented aging.\u003c\/p\u003e \u003cp\u003eComment.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eReferences.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex.\u003c\/b\u003e\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Clinical \u0026amp; internal medicine [\u003ca title=\"See our other books on Clinical \u0026amp; internal medicine\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Clinical%20\u0026amp;%20internal%20medicine%20%5BMJ%5D%22\"\u003eMJ\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52276179796248,"sku":"9780470319369","price":64.79,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470319369.jpg?v=1781364916","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/mild-cognitive-impairment-and-early-alzheimers-disease-detection-and-diagnosis-hardback-9780470319369","provider":"Freshly Printed Books","version":"1.0","type":"link"}